- Home
- Knowledge Base
- References
Saponins from Saponaria officinalis L. augment the efficacy of a Rituximab-immunotoxin.
Gilabert-Oriol R, Thakur M, Haussmann K, Niesler N, Bhargava C, Görick C, Fuchs H, Weng A (2016) Saponins from Saponaria officinalis L. augment the efficacy of a Rituximab-immunotoxin. Planta Med 82:1525-1531. doi: 10.1055/s-0042-110495
Summary: It is known that triterpenoidal saponins that come from Saponaria officinalis, the plant that saporin comes from, increases the cytotoxicity of saporin by modulating its intracellular trafficking. Investigators wanted to know if this could increase the therapeutic affect of Rituximab-Saporin. In the presence of saponins, Rituximab-Saporin had a 700-fold increase in efficacy. Concentrations of 0.0001-1nM of Anti-CD22-SAP (Cat. #IT-37) and 0.001-10nM of Anti-CD25-SAP (Cat. #IT-24) were also tested in vitro with saponins for comparison. They saw a 170-fold and 25-fold increase in cytotoxicity, respectively. All conjugates were tested on Ramos cells, and differing levels of receptor expression could explain the drastic differences in cytotoxicity enhancement.
Related Products: Anti-CD22-SAP human (Cat. #IT-37), Anti-CD25-SAP human (Cat. #IT-24)
The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL, Shen GL, Ghetie MA, May RD, Till M, Ghetie V, Uhr JW, Janossy G, Thorpe PE, Amlot P, Vitetta ES (1989) The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol 118(1):85-99. doi: 10.1016/0008-8749(89)90359-6 PMID: 2463099
Related Products: CD22 Mouse Monoclonal (Cat. #AB-36), Anti-CD22-SAP human (Cat. #IT-37)
Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW, Janossy G, Amlot P, Vitetta ES, Thorpe PE (1988) Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer 42(5):792-797. doi: 10.1002/ijc.2910420527 PMID: 3263328
Related Products: CD22 Mouse Monoclonal (Cat. #AB-36), Anti-CD22-SAP human (Cat. #IT-37)